• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic acquires drug/device maker TYRX for $160M

January 6, 2014 By drugdelivery

Medtronic nabs drug/device maker TYRX for $160M

Minnesota medical device giant Medtronic (NYSE:MDT) announced today that it acquired privately owned TYRX, maker of surgical infection prevention products.

The deal includes an up-front cash payment of $160 million as well as unspecified milestone-based payments, according to a press release.

The deal plays into the company’s relatively new ambition to broaden its scope beyond pure medical devices. Medtronic in August paid $200 million for Cardiocom LLC in cash in a bid to get into the disease management business and in September launched its ‘Hospital Solutions’ business.

The moves signal Medtronic’s continued foray into a larger healthcare arena, a choice that some Wall Street analysts warned may also suggest "challenging times ahead" for the device industry.

Newly acquired TYRX comes with a portfolio of FDA-cleared products, including the AIGISRx N antibacterial envelope as well as the newly cleared AIGISRx R fully resorbable antibacterial envelope. The products are designed to prevent surgical site infections, the AIGISRx N in spinal cord neurostimulator implantation and the AIGISRx R in surgeries for cardiac implantable electronic devices.

Surgical infections account for significant costs to the healthcare system, not to mention the risk to patients, and the risk increases when patients undergo additional surgeries beyond the device implant.

"While the risk of infection from an implanted pacemaker or defibrillator is low for most patients, repeated operative procedures after the initial device implant are associated with a substantial incremental risk of infection," Medtronic cardiac rhythm disease management president and senior vice president Pat Mackin said in prepared remarks. "This is estimated to cost the U.S. healthcare system more than $1 billion per year."

MDT shares started out strong this morning and were up 1.7% as of about 11:55 a.m. when they were trading at $59.33 apiece. Medtronic’s stock has gained about 3.7% since the start of the year.

Filed Under: Drug-Device Combinations Tagged With: Minnesota, Patient Safety, TYRX Inc.

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS